Abiopharma

🔍 Zanganeh Mahkam (Director)

Company: Summit Therapeutics Inc. (SMMT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 11,232 shares of Stock Option (right to buy) at $17.52 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 11,232.00 | transaction_form_type: 4 | Footnotes: F2, F1, F3

Footnotes:

• F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person's spouse remaining as a non-salaried director on each such vesting date.
• F2: The option was issued to the reporting person's spouse pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $98,400.
• F3: The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or any other purpose.